|
|
| | GSK 2033 Basic information |
| Product Name: | GSK 2033 | | Synonyms: | GSK 2033;LXR antagonist 2033;2,4,6-Trimethyl-N-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-N-[[5-(trifluoromethyl)-2-furanyl]methyl]benzenesulfonamide;Benzenesulfonamide, 2,4,6-trimethyl-N-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-N-[[5-(trifluoromethyl)-2-furanyl]methyl]-;GSK2033 >=98% (HPLC);Liver X receptor,Inhibitor,GSK 2033,inhibit,LXR,GSK2033,GSK-2033 | | CAS: | 1221277-90-2 | | MF: | C29H28F3NO5S2 | | MW: | 591.66 | | EINECS: | | | Product Categories: | | | Mol File: | 1221277-90-2.mol |  |
| | GSK 2033 Chemical Properties |
| storage temp. | 2-8°C | | solubility | DMF:5.0(Max Conc. mg/mL);8.45(Max Conc. mM)
DMSO:17.46(Max Conc. mg/mL);29.51(Max Conc. mM) | | form | powder | | color | white to beige |
| | GSK 2033 Usage And Synthesis |
| Uses | GSK 2033 is a potent LXR antagonist. | | Biochem/physiol Actions | GSK2033 is an antagonist of the nuclear receptor liver-X-receptor (LXR) with pIC50 values of 7.0 for LXRα and 7.4 for LXRβ. Treatment of murine CD41 T cells with GSK2033 enhanced cellular proliferation and Th1/Th2/Th17 differentiation. In another study, the conjugated linoleic acid (CLA)-induced expression of efflux protein ATP-binding-cassette transporter A1 (ABCA1) was completely abolished by preincubation with GSK2033, showing that CLA mediated regulation of ABCA-1 expression is LXR dependent. | | storage | Store at +4°C |
| | GSK 2033 Preparation Products And Raw materials |
|